Novel Drug Delivery System China 2011, will bring together both scientific and business leaders experienced in drug delivery, formulation, R&D, commercialization, business development from 20+ China pharmaceutical companies, 20+ multinational pharmaceutical companies to discuss and showcase latest regulatory, market trend, technology, commercialization based on multiple formats including inspiring keynote speeches, 2 interactive workshop, 2 panel discussions, 2 case studies, 8 interactive Q&A. There’s no better way for you to optimize your time, resources and learning scientific technology and gain business opportunity with 120+ high-level attendees than by attending NDDS China 2011. Check Agenda Details
Keynote Speakers Include:
| |
|
.jpg) |
|
|
Chairman
Li Chen
President, CEO/SAPA China Club President
Hua Medicine Limited |
|
|
|
 |
|
|
Pei Yuanying
Professor
Fudan University
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
|
|
Marie-Paule Benassi
1st counselor
EU Delegation in
|
|
|
|
 |
|
|
Chen Qinghua
Researcher
Shanghai Institute of Pharmaceutical Industry
|
| |
|
|
|
|
|
|
| |
|
 |
|
|
Richard Korsmeyer
Head, Business Development & Licensing for Pharmaceutical Sciences
Pfizer
|
|
|
|
 |
|
|
Marcel de Matas
Principal Scientist-Formulation Science
AstraZeneca
|
| |
|
|
|
|
|
|
| |
|
 |
|
|
Wei-Guo Dai
Fellow(Corporate Director Level), Drug Delivery & Device Development
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
|
|
|
 |
|
|
Wang Xinglin
Director, Formulation
Tianjin Institute of Pharmaceutical Research
|
| |
|
|
|
|
|
|
| |
|
 |
|
|
Liang Chaofeng
Deputy Director
Guangzhou Institute of Pharmaceutical Industry |
|
|
|
 |
|
|
Jin Fang
Director of Shanghai Engineering Research Center of Respiratory Medicine
Shanghai Institute of Pharmaceutical Industry |
| |
|
|
|
|
|
|
| |
|
 |
|
|
Lucy Xu
Group Head
Novartis
|
|
|
|
 |
|
|
Xu Yuhong
Professor, Pharmaceutical Department
Shanghai Jiaotong University |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
|
|
Zhixuan Wang
Senior Scientist, Chemical & Pharmaceutical Profiling
Novartis
|
|
|
|
 |
|
|
Guang Cheng
Director& Deputy General Manager
Jiangsu Engineering Research Center for Liposomal Drug
Nanjing Luye Sike Pharmaceutical Co., Ltd
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
|
|
Prof. Xian-ming Zeng
Sr. Director, Global Respiratory R&D
TEVA Branded Pharmaceutical Products R&D
|
|
|
|
 |
|
|
Ling Chen
VP, R & D Operations
GlaxoSmithKline
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
|
|
Ravi Shanker
Senior Research Fellow
Pfizer
|
|
|
|
 |
|
|
Jun Han
President
SOTA Pharmaceutical Inc.
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
.jpg) |
|
|
Jason Chen
Executive Director
Simcere Pharmaceutical Group
|
|
|
|
 |
|
|
Zhang Jundong
R&D Director, SinePharm
Shanghai Pharma
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
|
|
Ping Qineng
Professor
China Pharmaceutical University
|
|
|
|
 |
|
|
Weiping Yu
Chief Scientist
Libang Health Group Co. Ltd
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
|
|
Song Mingxian
Secretary General
China Pharmaceutical Excipients Committee (CPEC)
|
|
|
|
|
|
|
|
Regulation Environment
Registration of new NDDS/formulation products from SFDA, FDA, EU
Registration case study from pharmaceutical company
Market Trend & Commercialization Outlook
NDDS outlook for next 5-10 years in china and globally
NDDS R&D Trend from China’s big pharmas and international big pharmas
NDDS Commercialization
NDDS Updates and Technology/Platform
Oral Drug Delivery System , Inhalation Drug Delivery System , Injection Drug Delivery System, etc
Technologies: sustained / controlled release, bioavailability enhancement, nanoparticles,liposome, targeted DDS, solubility enhancement, etc.
More
|
|
Add to Calendar